Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 12/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
| ▸ | CLK2 | P49760 | 1/20 | 0.33 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.33 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.33 |
| ▸ | HIPK3 | Q9H422 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26941926 | 0.82 | CLK1 (0.33) | CLK1CLK2HIPK1HIPK2HIPK3 | |
| SCHEMBL22732516 | 0.78 | USP1 (0.36) | CLK1CLK2HIPK1HIPK2HIPK3 | |
| SCHEMBL22712461 | 0.75 | ALDH1A1 (0.56) | KDM4ENPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL22275580 | 0.75 | NPC1 (0.44) | KDM4ENPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL22712437 | 0.70 | ALDH1A1 (0.53) | KDM4ENPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL22732770 | 0.70 | RXRA (0.36) | CLK1CLK2HIPK1HIPK2HIPK3 | |
| SCHEMBL22745756 | 0.70 | RXRA (0.37) | CLK1CLK2HIPK1HIPK2HIPK3 | |
| SCHEMBL24389533 | 0.68 | PDE2A (0.32) | CLK1CLK2HIPK1HIPK2HIPK3 | |
| SCHEMBL22712492 | 0.68 | KDM4E (0.42) | KDM4ENPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL22732833 | 0.65 | KDM4E (0.35) | KDM4ENPC1ALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208387-B2 | Macrocyclic broad spectrum antibiotics | GENENTECH, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200377463-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | GENENTECH, INC. | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377463-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, CLPP, PEPD | MTOR 196/4885CLK1 2495/4885CLK2 3785/4885 |
| US-11208387-B2 | Macrocyclic broad spectrum antibiotics | MRPL21, CLPP, PEPD | MTOR 196/4885CLK1 2495/4885CLK2 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.